JPRN-jRCTs051180124已完成2 期
The study of COmbination therapy with Radium-223 and Enzalutamide in Osaka City University - CORE-OC
Kato Minoru0 个研究点目标入组 10 人开始时间: 2019年3月13日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
We could not evaluate the efficacy of Ra-223 for patients with metastatic castration-resistant prostate cancer that showed only PSA progression after enzalutamide treatment due to the small number of patients. However, There were no novel adverse events(AEs)or increase of the frequency of AEs in patients treated with combination of enzalutamide and Ra-223 compared with Ra223 monotherapy. This indicate that the combination of enzalutamide and Ra-223 could be tolerable for patients with mCRPC.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •1. Patients diagnosed as CRPC
- •2. Surgical or those who will be treated with luteinizing hormone-releasing
- •hormone(LHRH)agonists throughout the study period,
- •3.Patients who had >30% of PSA response to enzalutamide prior to enrollment,
- •4. Interval between PSA progression and enrollment is up to 6 months,
- •5. With bone metastases (>- 2 hot spots) on bone scintigraphy within previous 24 weeks,
- •6. No intention to use anti-cancer chemotherapy within the next 6 months,
- •7. Eastern Cooperative Oncology Group performance status (ECOG-PS)0-1,
- •8. Life expectancy >- 6 months,
- •9. Laboratory requirements within 30 days before enrollment:
- •Absolute neutrophil count (ANC) >- 1.5 x 10e9/L,
- •Platelet count >- 100 x 10e9/L,
- •Hemoglobin >- 10.0 g/dL,
- •Total bilirubin level -<1.5 institutional upper limit of normal (ULN),
- •Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) -<2.5 ULN,
- •Creatinine -< 1.5ULN, and estimated glomerular filtration rate (GFR)>- 30 mL/min/1.73 m2,
- •10. Age >- 20,
- •11. Ability to understand and the willingness to sign a written informed consent (IC).
排除标准
- •1.Prior chemotherapy or planned treatment with chemotherapy,
- •2.PSA progression within 3 months after initiation of enzalutamide
- •3.Prior treatment with corticosteroids, estramustine or abiraterone acetate,
- •4.Any systemic radiotherapy with strontium-89, samarium-153,
- •rhenium-186 or rhenium-188 for the treatment of bone metastases,
- •5.Had history of gastrointestinal bleeding or ulcer within 3 months prior to study entry,
- •6.History of visceral metastasis, or presence of visceral metastasis detected by screening imaging examinations,
- •7.History of or known brain metastasis,
- •8.Malignant lymphadenopathy>-1.5 cm in short axis,
- •9.Imminent or established spinal cord compression based on clinical findings and/or MRI (Magnetic Resonance Imaging),
- •10.Any other serious illness or medical condition
- •11.Substance abuse, medical, psychological, or social conditions that might interfere with the subject's participation in the study or evaluation of the study Results
- •12.Those who judged to be inappropriate by the principal investigator or coinvestigator.
研究者
相似试验
撤回
不适用
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review StudyProstatic Neoplasms, Castration-ResistantNCT03325127Bayer
已完成
不适用
Response measurement study in metastatic castration-resistant prostate cancer patients, treated with radium-223, to improve early response evaluation and understand the radium-223 induced immune responseNL-OMON26890Bayer28
招募中
不适用
The Radium-select StudyNCT06659926The Netherlands Cancer Institute60
已完成
不适用
The study of combination therapy with radium-223 and enzalutamide in Osaka City UniversityCastration-resistant prostate cancer with bone metastasesJPRN-UMIN000029422Osaka City University Graduate School of Medicine10
已完成
不适用
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223Prostate Cancer MetastaticBone MetastasesNCT03223597The Netherlands Cancer Institute300